Peptidream Inc.

PeptiDream Inc. is a biopharmaceutical company that discovers and develops constrained peptides, small molecules, and peptide-drug conjugate therapeutics. Its drug discovery efforts are based on the Peptide Discovery Platform System, which integrates technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, enabling rapid identification of novel compounds with high potency and selectivity for protein targets. The company is developing 64Cu-ATSM for malignant brain tumor and 177Lu/64Cu-PSMA I&T for prostate cancer, both in phase 3 clinical development, as well as a GhR antagonist for acromegaly in phase 2. It is also developing 225Ac/68Ga-GPC3 for hepatocellular carcinoma, 177Lu/68Ga-FAP for pancreatic, lung, breast, and colon cancer, 225Ac/64Cu-CA9 for renal cell carcinoma, 18F-PD-L1 for cancer, CD38-ARM for multiple myeloma, S2-protein inhibitors for COVID-19, and merck, all in phase 1. In addition, it is developing novartis and rayzeBio for cancer, 225Ac/64Cu-CLDN18.2 for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 for head and neck cancer, KIT inhibitors for allergic diseases, oral myostatin inhibitors for obesity/muscle disease, and oral IL-17A/F inhibitors for inflammatory diseases such as psoriasis, all in preclinical development. The company is also involved in the research, development, manufacture, and sale of pharmaceuticals in the radiopharmaceutical (RI) and non-RI fields. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.